[{"orgOrder":0,"company":"Cellular Sciences","sponsor":"General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ General University Hospital, Prague","highestDevelopmentStatusID":"10","companyTruncated":"Cellular Sciences \/ General University Hospital, Prague"},{"orgOrder":0,"company":"Cellular Sciences","sponsor":"Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","highestDevelopmentStatusID":"9","companyTruncated":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague"},{"orgOrder":0,"company":"Cellular Sciences","sponsor":"Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","highestDevelopmentStatusID":"9","companyTruncated":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Undisclosed"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Sodium Pyruvate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cellular Sciences

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Cellular Sciences

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 14, 2023

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : General University Hospital, Prague

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with ...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 05, 2021

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Cellular Sciences

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Cellular Sciences

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II/ Phase III

                          Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Post-Acute COVID-19 Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 04, 2021

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Cellular Sciences

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Cellular Sciences

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II/ Phase III

                          Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 01, 2021

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 07, 2020

                          Lead Product(s) : Sodium Pyruvate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank